Supii Capstone Project-5.pptx project report
- 1. Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru USN- 4VV23BA099 Presentation on Enterprise Analysis of “Mankind Pharma Limited” Internal Guide Dr. Shwetha G Y Assistant Professor Dept. of Business Administration VVCE, Mysuru Presented By Ms. Supriya G USN:4VV23BA099 Dept. of Business Administration VVCE, Mysuru
- 2. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Company Overview About: • Mankind Pharma, founded in 1991, incorporated in 1995, is based in New Delhi. Mankind Pharma is an India’s largest pharmaceutical companies( By domestic sales) and are engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. • The company has three major brands: Manforce, Prega News, and Gas-O-Fast. • Mankind is India's fourth-largest pharmaceutical company by domestic sales. Around 34 foreign countries in Asia, Africa, South-East Asia, the Gulf of Mexico. USN- 4VV23BA099
- 3. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Mission and Vision: • Vision of Mankind Pharma is, "To be a global pharmaceutical company, most admired for its Affordability, Quality, and Accessibility of products." • Mission of Mankind Pharma is, "To be able to provide cost-effective, innovation-based superior quality pharmaceutical products across the globe, to improve the lives of the patients." USN- 4VV23BA099
- 4. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru A. Promoters of Mankind Pharma Limited: Ramesh Juneja(Chairman and Whole-Time Director), who has over 31 years of work experience in the pharmaceuticals industry, and Rajeev Juneja (Vice Chairman and Managing Director), who has over 29 years of experience in the pharmaceuticals industry. B. Present Board Of Directors: The Board of Directors of Mankind Pharma Ltd. consists of ten members as of March 31, 2023. This includes four Executive Directors, one Non-executive Non-independent Director, and five Non-executive independent Directors, including one woman Director. USN- 4VV23BA099
- 5. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru USN- 4VV23BA099 Name Designation Mr. Ramesh Juneja Chairman and Whole Time Director Mr. Rajeev Juneja Vice Chairman and Managing Director Mr. Sheetal Arora Chief Executive Officer and Whole Time Director Mr. Satish Kumar Sharma Whole Time Director Mr. Surendra Lunia Independent Director Mr.Tilokchand Punamchand Ostwal Independent Director Mr. Bharat Anand Independent Director Mr. Vivek Kalra Independent Director Ms. Vijaya Sampath Independent Director
- 6. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru C. Number of Units operating: • As of March 2023, Mankind Pharma Limited has 25 manufacturing facilities and 6 Research & Development centers across India, in the states of Himachal Pradesh, Sikkim, Rajasthan, Andhra Pradesh, Maharashtra and Uttarakhand. As of December 2022, the company also had 4,121 manufacturing personnel. USN- 4VV23BA099
- 7. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru D. Number of Employees: As of March 2023, Mankind Pharma has over 22,000 employees. E. Market Share: Current Price 2,102/share ₹ USN- 4VV23BA099
- 8. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Industry Overview • The pharmaceutical industry is a critical sector in medicine that discovers, develops, produces, and markets pharmaceutical drugs for various therapeutic uses. Its origins can be traced back to the mid-1800s when local apothecaries began expanding their roles from distributing botanical drugs to wholesale manufacture. • Pharma Industry contributes about 1.32% to Gross Domestic Product(GDP) USN- 4VV23BA099
- 9. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Competitors Details • Competitors of Mankind Pharma include Sun Pharmaceutical Industries Ltd, Cipla Ltd, Divis Labs, Zydus Lifesciences Ltd, Dr. Reddy's Laboratories Ltd, Torrent Pharma, Lupin Ltd. USN- 4VV23BA099
- 10. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Core Values Mankind Pharma strongly believes in and follows its Core Values: • Emprovement: Mankind Pharma believes in empowering its employees to drive success and growth within the organization. • Positive Work Culture: The company emphasizes creating a positive work culture that promotes collaboration, innovation, and employee well-being. • Innovation: Innovation is a key value at Mankind Pharma, driving the continuous improvement of products and processes. • Quality:Maintaining superior quality in all aspects of its operations is a fundamental value for Mankind Pharma. USN- 4VV23BA099
- 11. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Products/Services They provide over 1000 supreme-quality products in 22 different forms, covering various therapeutic areas such as anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Consumer Healthcare Products: Condoms: Differentiated condom brands. Antacids: Antacid powders. Pregnancy Detection: Pregnancy test products. Anti-Acne Preparations: Gels and creams for acne treatment. Vitamin and Mineral Supplements: A range of supplements. Corporate Social Responsibility (CSR):. In FY 2022-23, they spent Rs. 20 crore on CSR activities. USN- 4VV23BA099
- 12. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Financial Performance USN- 4VV23BA099 Year Mar-19 Mar-20 Mar-21 Mar-22 Mar-23 Revenue (in Rs. Cr.) 3,941.823 4,888.6 5,677.68 7,419.77 8,289.94 Jan-19 Jan-20 Jan-21 Jan-22 Jan-23 0.00 1,000.00 2,000.00 3,000.00 4,000.00 5,000.00 6,000.00 7,000.00 8,000.00 9,000.00 Year Revenue
- 13. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Ratio Analysis USN- 4VV23BA099 2019 2020 2021 2022 2023 Debt Equity Ratio 0.09 0.03 0.01 0.07 0.05 Current Ratio 1.59 1.64 1.9 1.48 1.38 Fixed Assets Turnover Ratio 5.09 4.77 4.71 3.31 2.3 2019 2020 2021 2022 2023 0 1 2 3 4 5 6 0 0.02 0.04 0.06 0.08 0.1 Debt Equity Ratio Current Ratio Fixed Assets Turnover Ratio Year Ratios
- 14. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Track Record of Success USN- 4VV23BA099
- 15. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru USN- 4VV23BA099
- 16. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Future Projects • Expansion into International Markets • Diversification of Product Portfolio • Focus on Research and Development • Sustainable Practices USN- 4VV23BA099
- 17. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru Conclusion Mankind Pharma’s journey from its inception to becoming a major player in the pharmaceutical industry showcases its resilience, strategic decisions, and commitment to quality healthcare. As the company continues to expand, it should maintain its focus on innovation, affordability, and meeting the healthcare needs of millions of people. Learning Objectives: • Research Skills • Communication Skills • Critical Thinking Bibliography: - https://www.mankindpharma.com - https://www.capitaline.com USN- 4VV23BA099
- 18. Vidyavardhaka College of Engineering, Mysuru Department of Business Administration, Vidyavardhaka College of Engineering, Mysuru USN- 4VV23BA099 Thank You
Editor's Notes
- #1: Good afternoon everyone, I am Supriya from 1st year MBA A Sec . I am here to present enterprise analysis of mankind pharma ltd….
- #2: 50,00,000
- #7: 4.5%in the pharmaceutical market in 2025 is expected to reach 2,919 96.6%=india market 4%=Internationally(2022)
- #9: Based on market capitalisation(in crores) 6th 3,65,178.78 1,13,915.46 mankind:95,139.75
- #11: Education(children&women) ,health care(free medicines&medical facilities to poor and needy) ,poverty ,safe drinking water,livelihood(setting up homes and hostels for women and old age people,day care centers for senior citizens #1=rank in prescriptions #3=rank in product volume
- #12: Major factor 20% growth seen in domestic business, led by 1.3x faster growth in the chronic therapies compared to others.(out performance) Chronic therapies=medical treatment administrated over a long period of time.. It is profitable which crossed revenue milestone of 10,000 cr, during 2023-24
- #13: Generating higher profits that can be reinvested into the business ,paying of existing debts,its shows potentially reducing its financial risk(2:1)(debt a company has compared to its assets) Increase in short term debt and decrease in CA / BOTH(2:1) Over-investment in Fixed Assets,New Product,Time Delay(2.5 or more)
- #16: Already expanded its footprint into 34 international mrkt..- including north amer,Africa and asia Withover 1,000 products in 17 therapeutic areas